PepGen (PEPG) stock
PEPG · PepGen Inc. · NASDAQ
- Market cap
- $370.9M
- Shares out
- 94.3M
What is the latest news on PEPG stock?
PEPG rose 2.88% to $3.94 on Nov 19, 2026. No PEPG story in the last two days; the most recent is below.
SCHEDULE 13D/A - PepGen Inc. (0001835597) (Subject)
All PEPG newsWhen does PepGen report earnings?
PepGen last reported on Mar 23, 2023, the date it announced on Mar 16, 2023.
PEPG earnings historyWho owns the most PEPG stock?
Ra Capital Management, L.p. was the largest reported holder of PEPG at the end of Q2 2026, with 20,064,545 shares worth $36.1 million. Next came Commodore Capital LP ($8.1 million) and Viking Global Investors LP ($6.3 million). In all, 72 institutions reported $93.7 million of PEPG in their 13F filings.
All PEPG fund holdersAre insiders buying or selling PEPG?
Insiders are buying. In the last 90 days 1 insider bought $43.1 million of PEPG in trades reported on Form 4. The latest: Ra Capital Management, L.P. bought $43.1 million, reported on Nov 17, 2026.
PEPG insider tradesFinancial highlights
Full financials- Net income, TTM
- -$73.31M
- Free cash flow, TTM
- -$63.28M
- Cash
- $21.96M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13D/A filed by PepGen Inc.SCHEDULE 13D/A - PepGen Inc. (0001835597) (Subject)
- INSIDERDirector Ra Capital Management, L.P. bought $43,125,000 worth of shares (8,625,000 units at $5.00) (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- SECPepGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- SECSEC Form 424B5 filed by PepGen Inc.424B5 - PepGen Inc. (0001835597) (Filer)
- PRPepGen Announces Pricing of $125 Million Public OfferingPepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today announced the pricing of a public offering of 25,000,000 shares of its common stock at a price to the public of $5.00 per share. The aggregate gross proceeds to PepGen from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by PepGen. In addition, PepGen has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of common stock at the public offering price, less the underwriting discounts and commi
- SECSEC Form 424B5 filed by PepGen Inc.424B5 - PepGen Inc. (0001835597) (Filer)
- PRPepGen Announces Proposed $125.0 Million Public Offering of Common StockPepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today announced the launch of a public offering of $125.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, PepGen intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All of the securities to be sold in the prop
- ANALYSTPepGen upgraded by BofA Securities with a new price targetBofA Securities upgraded PepGen from Underperform to Neutral and set a new price target of $6.00
- SECPepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- SECSEC Form 10-Q filed by PepGen Inc.10-Q - PepGen Inc. (0001835597) (Filer)
- PRPepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights– Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures – – 12.5 mg/kg FREEDOM2-DM1 cohort fully enrolled, with participants having received up to three doses; results expected in 1H 2027 – – FREEDOM-OLE 10 mg/kg safety and 5 mg/kg clinical data expected in January 2027 – – Well-funded with $104.8M of cash as of September 30, 2026, sufficient to fund operations into 2028 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today reported financial results and recent c
- PRPepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures- Mean splicing correction of 46.5% following four monthly doses of PGN-EDODM1, five of six participants having more than 20% splicing correction and four participants exceeding 50% splicing correction – - Video Hand Opening Time (vHOT), a measure of myotonia, improved by 3.9 seconds (52.7%) from baseline at Week 16 - - Meaningful functional improvements observed across measures of strength, ambulation, and mobility, supporting the potential for broad clinical benefit in DM1 - - PGN-EDODM1 was generally well tolerated, with no serious or severe adverse events or dose-limiting toxicities reported - - Conference call scheduled today at 8:00 a.m. ET - PepGen Inc. (NASDAQ:PEPG), a cli
- SECPepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- PRPepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg – – 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November – – Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 – – Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological di
- SECSEC Form 10-Q filed by PepGen Inc.10-Q - PepGen Inc. (0001835597) (Filer)
- PRPepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review– DSMB also recommended dose escalation in FREEDOM-OLE from 5 mg/kg to 10 mg/kg – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that an independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study evaluating PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) into the third and highest multiple ascending dose (MAD) cohort of 12.5 mg/kg, with no recommended changes to the study protocol. The DSMB also recommended dose escalation in the
- PRKalaris Appoints Laurie Keating to Board of DirectorsBERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In conjunction with the announcement of Ms. Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board of Directors. "We’re delighted to welcome Laurie to the Kalaris Board of Directors. She has extensive strategic, operational, and legal expertise spanning multiple therapeutic areas and development stages. Laurie will be
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - PepGen Inc. (0001835597) (Issuer)
- SECPepGen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PepGen Inc. (0001835597) (Filer)
- INSIDERSEC Form 4 filed by Director Wyman Lisa4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Director Resnick Joshua4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Director Mayer Howard4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Director Finer Mitchell H.4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Director Dable Habib J4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Director Henson Heidi4 - PepGen Inc. (0001835597) (Issuer)
PEPG rankings
- SEC Filings5(42%)
- Earnings2(17%)
- Offering2(17%)
- Analyst1(8%)
- Insider1(8%)
- 13D/G1(8%)
PepGen Inc. (PEPG) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 12 wire items for PEPG, including 5 SEC filings, 2 earnings updates and 2 offerings. The most recent was published Nov 17, 2026.
PEPG FAQ
9 questionsWhat does PepGen Inc. do?
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is...Is PEPG profitable?
No. PepGen Inc. reported a net loss of $73.31M for the twelve months ended Sep 30, 2026.How much cash and debt does PEPG have?
PepGen Inc. reported $21.96M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does PEPG stock trade?
PepGen Inc. (PEPG) is listed on NASDAQ.What sector and industry is PEPG in?
PepGen Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PepGen Inc. go public?
PepGen Inc. (PEPG) completed its IPO in 2022.What are analysts saying about PEPG?
Across the last 6 analyst actions on PepGen Inc., there was 1 upgrade and 2 downgrades. The most recent action was from BofA Securities: Neutral with a $6.00 price target on 2026-11-10.What companies are similar to PEPG?
Notable peers in the same industry include DYN (Dyne Therapeutics Inc.), WVE (Wave Life Sciences Inc.), TRDA (Entrada Therapeutics Inc.), SRPT (Sarepta Therapeutics Inc.), EWTX (Edgewise Therapeutics Inc.). Compare PEPG side-by-side with any of them on Quantisnow.How can I track PEPG on Quantisnow?
Quantisnow aggregates PepGen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PEPG to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change